Literature DB >> 21106907

The prototypical ranitidine analog JWS-USC-75-IX improves information processing and cognitive function in animal models.

Alvin V Terry1, Jerry J Buccafusco, Elizabeth J Herman, Patrick M Callahan, Wayne D Beck, Samantha Warner, Leah Vandenhuerk, Kristy Bouchard, Gary M Schwarz, Jie Gao, James M Chapman.   

Abstract

This study was designed to evaluate further a prototypical ranitidine analog, JWS-USC-75-IX, [(3-[[[2-[[(5-dimethylaminomethyl)-2-furanyl]methyl]thio]ethyl]amino]-4-nitropyridazine, JWS], for neuropharmacologic properties that would theoretically be useful for treating cognitive and noncognitive behavioral symptoms of neuropsychiatric disorders. JWS was previously found to inhibit acetylcholinesterase (AChE) activity, serve as a potent ligand at muscarinic M₂ acetylcholine receptors, and elicit positive effects on spatial learning, passive avoidance, and working memory in rodents. In the current study, JWS was evaluated for binding activity at more than 60 neurotransmitter receptors, transporters, and ion channels, as well as for inhibitory activity at AChE and butyrylcholinesterase (BChE). The results indicate that JWS inhibits AChE and BChE at low (micromolar) concentrations and that it is a functional antagonist at M₂ receptors (K(B) = 320 nM). JWS was subsequently evaluated orally across additional behavioral assays in rodents (dose range, 0.03-10.0 mg/kg) as well as nonhuman primates (dose range, 0.05-2.0 mg/kg). In rats, JWS improved prepulse inhibition (PPI) of the acoustic startle response in nonimpaired rats and attenuated PPI deficits in three pharmacologic impairment models. JWS also attenuated scopolamine and (-)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate (MK-801)-related impairments in a spontaneous novel object recognition task and a five-choice serial reaction time task, respectively. In monkeys, JWS elicited dose-dependent improvements of a delayed match-to-sample task as well as an attention-related version of the task where randomly presented (task-relevant) distractors were presented. Thus, JWS (potentially via effects at several drug targets) improves information processing, attention, and memory in animal models and could potentially treat the cognitive and behavioral symptoms of some neuropsychiatric illnesses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21106907      PMCID: PMC3061527          DOI: 10.1124/jpet.110.175422

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  40 in total

1.  A new and rapid colorimetric determination of acetylcholinesterase activity.

Authors:  G L ELLMAN; K D COURTNEY; V ANDRES; R M FEATHER-STONE
Journal:  Biochem Pharmacol       Date:  1961-07       Impact factor: 5.858

Review 2.  Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.

Authors:  S Miyamoto; G E Duncan; C E Marx; J A Lieberman
Journal:  Mol Psychiatry       Date:  2005-01       Impact factor: 15.992

3.  Selective serotonin 5-HT2A receptor antagonist EMD 281014 improves delayed matching performance in young and aged rhesus monkeys.

Authors:  Alvin V Terry; Jerry J Buccafusco; Gerd D Bartoszyk
Journal:  Psychopharmacology (Berl)       Date:  2004-12-24       Impact factor: 4.530

Review 4.  The catalepsy test: its ups and downs.

Authors:  P R Sanberg; M D Bunsey; M Giordano; A B Norman
Journal:  Behav Neurosci       Date:  1988-10       Impact factor: 1.912

Review 5.  Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders.

Authors:  Moussa B H Youdim; Jerry J Buccafusco
Journal:  Trends Pharmacol Sci       Date:  2005-01       Impact factor: 14.819

6.  Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats.

Authors:  Carrie K Jones; Elizabeth Lutz Eberle; David B Shaw; David L McKinzie; Harlan E Shannon
Journal:  J Pharmacol Exp Ther       Date:  2004-12-01       Impact factor: 4.030

Review 7.  Cholinergic markers in Alzheimer disease and the autoregulation of acetylcholine release.

Authors:  R Quirion
Journal:  J Psychiatry Neurosci       Date:  1993-11       Impact factor: 6.186

Review 8.  Schizophrenia, sensory gating, and nicotinic receptors.

Authors:  L E Adler; A Olincy; M Waldo; J G Harris; J Griffith; K Stevens; K Flach; H Nagamoto; P Bickford; S Leonard; R Freedman
Journal:  Schizophr Bull       Date:  1998       Impact factor: 9.306

9.  Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat.

Authors:  R S Mansbach; M A Geyer
Journal:  Neuropsychopharmacology       Date:  1989-12       Impact factor: 7.853

10.  Symposium overview: the use of delayed matching-to-sample procedures in studies of short-term memory in animals and humans.

Authors:  M G Paule; P J Bushnell; J P Maurissen; G R Wenger; J J Buccafusco; J J Chelonis; R Elliott
Journal:  Neurotoxicol Teratol       Date:  1998 Sep-Oct       Impact factor: 3.763

View more
  7 in total

Review 1.  CNTRICS final animal model task selection: control of attention.

Authors:  C Lustig; R Kozak; M Sarter; J W Young; T W Robbins
Journal:  Neurosci Biobehav Rev       Date:  2012-06-06       Impact factor: 8.989

Review 2.  Neurobiology of nAChRs and cognition: a mini review of Dr. Jerry J. Buccafusco's contributions over a 25 year career.

Authors:  Alvin V Terry; Michael W Decker
Journal:  Biochem Pharmacol       Date:  2011-06-12       Impact factor: 5.858

Review 3.  Alzheimer's disease and age-related memory decline (preclinical).

Authors:  Alvin V Terry; Patrick M Callahan; Brandon Hall; Scott J Webster
Journal:  Pharmacol Biochem Behav       Date:  2011-02-24       Impact factor: 3.533

4.  The prominent role of stimulus processing: cholinergic function and dysfunction in cognition.

Authors:  Maura L Furey
Journal:  Curr Opin Neurol       Date:  2011-08       Impact factor: 5.710

5.  Synthesis and biological evaluation of ranitidine analogs as multiple-target-directed cognitive enhancers for the treatment of Alzheimer's disease.

Authors:  Jie Gao; Narasimha Midde; Jun Zhu; Alvin V Terry; Campbell McInnes; James M Chapman
Journal:  Bioorg Med Chem Lett       Date:  2016-10-06       Impact factor: 2.823

6.  Facilitation of short-term memory by histaminergic neurons in the nucleus accumbens is independent of cholinergic and glutamatergic transmission.

Authors:  M M Kraus; H Prast; A Philippu
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

Review 7.  Use of Push-Pull Superfusion Technique for Identifying Neurotransmitters Involved in Brain Functions: Achievements and Perspectives.

Authors:  Michaela M Kraus; Athineos Philippu
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.